Kymera Therapeutics, Inc.
Financials
Valuation Metrics
Kymera Therapeutics, Inc.'s Market Cap is $9.75B. At end of 2025 it was $6.57B. Ranked #940 of 3,121 in US market (top 30%), #303 of 1,463 on NASDAQ (top 21%), #46 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 17%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $9.75B | US#940/3,121 Sec#46/266 |
| Revenue | $105M | US#2,692/3,121 Sec#124/266 |
| Net Income | $-300M | US—/3,121 Sec—/266 |
| Total Assets | $1.65B | US#2,209/3,121 Sec#64/266 |
| Net Assets | $1.51B | US#1,471/3,121 Sec#45/266 |
| Employees | 273 | US#2,438/3,121 Sec#116/266 |
| Value | ||
| P/B | 6.46x | US#2,394/3,121 Sec#162/266 |
| P/S | 92.83x | US#2,943/3,121 Sec#176/266 |
| FCF Yield | -2.44% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -19.85% | US#2,482/3,121 Sec#98/266 |
| ROA | -18.21% | US#2,778/3,121 Sec#125/266 |
| Op. Margin | -333.54% | US#2,794/3,121 Sec#147/266 |
| Revenue Growth | 134.82% | US#74/3,121 Sec#27/266 |
| Financial Health | ||
| Debt Ratio | 9.27% | US#101/3,121 Sec#47/266 |
| Total Debt | $82M | US#2,491/3,121 Sec#130/266 |
| FCF | $-238M | US#2,811/3,121 Sec#221/266 |
| Cash | $124M | US#2,076/3,121 Sec#154/266 |
| Current Ratio | 9.83x | US#263/3,121 Sec#83/266 |
| Performance | ||
| 1Y Return | 146.22% | US#111/3,121 Sec#45/266 |
| 1M Return | -2.39% | US#1,280/3,121 Sec#118/266 |
| From 52W High | -8.90% | US#620/3,121 Sec#46/266 |
| 1Y MDD | -27.74% | US#1,258/3,121 Sec#76/266 |
| Trading | ||
| Volume | 563,752 shares | US#1,910/3,121 Sec#198/266 |
| Trading Value | $67M | US#1,069/3,121 Sec#79/266 |
| Per Share | ||
| EPS | $-3.64 | US—/3,121 Sec—/266 |
| BPS | $18.35 | US#1,330/3,121 Sec#33/266 |
Company Info
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.